Funding and Acknowledgements

The Breast Cancer Surveillance Consortium and its data collection activities are funded by the National Cancer Institute (P01CA154292). The collection of cancer and vital status data is supported in part by several state public health departments and cancer registries throughout the U.S. A full description of these sources is below. We thank the participating women, mammography facilities, and radiologists for the data they have provided for this work. 

CANCER REGISTRY and Vital Status ACKNOWLEDGEMENT

The collection of cancer incidence and vital status data used in this study was supported, in part, by:

  • The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries, under cooperative agreement 1NU58DP007156; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors;
  • The Vermont Cancer Registry, supported in part by cooperative agreement NU58DP003911-05-00 awarded to the Vermont Department of Health from the Centers for Disease Control and Prevention;
  • The Cancer Surveillance System of the Fred Hutchinson Cancer Research Center, which is funded by contracts N01-CN-67009, N01-PC-35142, N01-PC-2010-00029, N01-PC-2013-00012, HHSN261201300012I, N01-PC-2018-00004, and HHSN261201800004I from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute with additional support from the Fred Hutchinson Cancer Research Center and the State of Washington;
  • The New Hampshire State Cancer Registry is supported by the Centers for Disease Control (CDC) and Prevention's National Program of Cancer Registries (NPCR) through cooperative agreement NU58DP007115 awarded to the New Hampshire Department of Health and Human Services, Division of Public Health Services, Bureau of Disease Control and Health Statistics, Health Statistics and Data Management Section;
  • The North Carolina Central Cancer Registry, which is partially supported by the Centers for Disease Control and Prevention, NC Cancer Prevention and Control Program for State, territorial and Tribal Organizations, under cooperative agreement number NU58DP007121;
  • The Colorado Central Cancer Registry, which is partially supported by the Colorado State General Fund and the federal Centers for Disease Control and Prevention (National Program of Cancer Registries) under Cooperative Agreement U58000848;
  • The New Mexico Tumor Registry supported, in part, by National Cancer Institute (NCI) contract NO1-PC-35138 and by the University of New Mexico Cancer Center, a recipient of NCI Cancer Support Grant P30-CA118100.
  • Manuscripts including data from the Metro Chicago Breast Cancer Registry were supported in part by the Illinois Department of Public Health, Illinois State Cancer Registry which is partially supported by the Centers for Disease Control and Prevention under cooperative agreement DP12-120504CONT15.

The ideas and opinions expressed herein are those of the authors and endorsement by the State of California, the California Department of Public Health; Illinois Department of Public Health; New Hampshire Department of Health and Human Services; the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred.